| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HLGN | Common Stock | Options Exercise | $140K | +1.56M | +58.35% | $0.09 | 4.23M | Jun 7, 2023 | Direct | |
| transaction | HLGN | Common Stock | Sale | -$390K | -1.56M | -36.85% | $0.25 | 2.67M | Jun 7, 2023 | Direct | F1 |
| transaction | HLGN | Common Stock | Options Exercise | $18.4K | +204K | +7.64% | $0.09 | 2.88M | Jun 8, 2023 | Direct | |
| transaction | HLGN | Common Stock | Sale | -$44.9K | -204K | -7.1% | $0.22 | 2.67M | Jun 8, 2023 | Direct | F1 |
| holding | HLGN | Common Stock | 414K | Jun 7, 2023 | See footnote | F2 | |||||
| holding | HLGN | Common Stock | 16.2K | Jun 7, 2023 | See footnote | F3 | |||||
| holding | HLGN | Common Stock | 15.5M | Jun 7, 2023 | See footnote | F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HLGN | Employee Stock Option (right to buy) | Options Exercise | $0 | -1.56M | -69.67% | $0.00 | 679K | Jun 7, 2023 | Common Stock | 1.56M | $0.09 | Direct | F5, F6 |
| transaction | HLGN | Employee Stock Option (right to buy) | Options Exercise | $0 | -204K | -30.09% | $0.00 | 475K | Jun 8, 2023 | Common Stock | 204K | $0.09 | Direct | F5, F6 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.21 to $0.27, inclusive on 6/7/2023 and prices ranging from $0.21 to $0.24, inclusive on 6/8/2023. Mr. Gross undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnote (1) to this Form 4 |
| F2 | These shares are held by The Gross Goodstein Living Trust (the "Trust") of which Mr. Gross is a co-trustee. Mr. Gross may be deemed to beneficially own these shares. Mr. Gross disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| F3 | These shares are held by Idealab Studio, LLC ("Idealab Studio"), for which Mr. Gross serves as chairman and chief executive officer. The Trust owns a majority of the class of securities of Idealab Studio entitled to elect two managers to Idealab Studio's board of managers. Mr. Gross may be deemed to beneficially own these shares. Mr. Gross disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| F4 | These shares are held by Idealab Holdings, LLC ("Idealab Holdings"), which is a wholly owned subsidiary of Idealab, a California corporation ("Idealab"). Idealab is managed by a board of directors (the "Idealab Board") including Mr. Gross. Mr. Gross may be deemed to beneficially own these shares. Mr. Gross disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| F5 | The options vested and became exercisable in equal monthly installments commencing December 6, 2018, subject to Mr. Gross's continuous service which ceased effective February 5, 2023. |
| F6 | The options are exercisable through the indicated expiration date pursuant to an extension granted by the Issuer. The original expiration date was approximately 10 years from the initial vesting date of options with the same exercise price. |